Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ABMD crawled time : 19:00 save search
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
Published: 2022-10-20 (Crawled : 19:00) - biospace.com/
ABMD | $381.02 0.06% 0.07%
|
Health Technology
|
| O: 0.22%
H: 0.81%
C: -0.5%
heart
Worldwide Cardiac Monitoring & Cardiac Rhythm Management Industry to 2025 - Competitive Analysis & Impact of COVID-19
Published: 2021-04-16 (Crawled : 19:00) - prnewswire.com
SYK | $325.43 -0.62% 0.0% 1.8M
|
Health Technology
| Email alert
Add to watchlist
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
| Email alert
Add to watchlist
LIVN | $52.31 -0.85% -0.86% 430K
|
Health Technology
| Email alert
Add to watchlist
OSIS | $135.65 1.35% 1.33% 95K
|
Electronic Technology
| Email alert
Add to watchlist
PHG | $19.98 0.0% 540K
|
Health Technology
| Email alert
Add to watchlist
GE | News | $148.06 -3.19% 0.0% 9.5M
|
Electronic Technology
| Email alert
Add to watchlist
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
| Email alert
Add to watchlist
ABMD | $381.02 0.06% 0.07%
|
Health Technology
| Email alert
Add to watchlist
covid
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.